MENLO PARK, Calif., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced that it will host an Investor Symposium in New York City on September 15, 2016. The event will bring together leading experts in the GHD space to share their knowledge and treatment experience. Topics to be discussed include GHD treatment approaches, treatment expectations for pediatric GHD (PGHD), current data and experience with somavaratan in the treatment of PGHD, as well as a treatment overview and top-line somavaratan data for adult GHD. The Versartis management team will also provide a corporate and clinical update and review upcoming milestones. Question and answer sessions with the physician presenters and Versartis management team will follow the formal remarks.
Beverly M K Biller, MD-Professor of Medicine, Harvard Medical School & Physician in Medicine, Neuroendocrine Unit, Massachusetts General Hospital
Alan D. Rogol, MD, PhD-Professor Emeritus, Pediatrics and Pharmacology, the University of Virginia School of Medicine
Michael Stalvey, MD,—Assistant Professor & Fellowship Program Director, Department of Pediatrics, University of Alabama at Birmingham School of Medicine
Event and Webcast Details
The meeting will be held on Thursday, September 15, 2016 from 8:00-10:30 am ET in New York City. Analysts and investors may register for the event by emailing name, company, and phone number to IR@versartis.com. A live webcast of the Versartis Investor Symposium may be accessed in the investor relations section of Versartis' website at www.versartis.com. A replay of the presentation will be available for 90 days.
About Versartis, Inc.
Versartis, Inc. is an endocrine-focused biopharmaceutical company initially developing somavaratan, a novel, long-acting form of recombinant human growth hormone in late-stage clinical trials for the treatment of GHD in children and adults. Somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance and, therefore, treatment outcomes. For more information on Versartis, visit www.versartis.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions or current expectations concerning, among other things, plans and timing of our clinical trials and the potential for eventual regulatory approval of somavaratan. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. We discuss many of these risks in greater detail under the heading "Risk Factors" contained in our Annual Report on Form 10-K for the year ended December 31, 2015 and in our Quarterly Report on Form 10-Q for the three months ended June 30, 2016, which are on file with the Securities and Exchange Commission (SEC). Forward-looking statements are not guarantees of future performance, and our actual results may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release and we assume no obligation to update our forward-looking statements after the date of this press release.
Contacts: Corporate & Investors: Joshua Brumm Chief Financial Officer (650) 963-8582 IR@versartis.com Corporate Communications: Christine Labaree Evergreen Communications (650) 600-1697 email@example.com Investors: Nick Laudico/David Burke The Ruth Group (646) 536-7030/7009 firstname.lastname@example.org email@example.com